Pemphigus Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Red crusty plaques in a young man
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562411.ABSTRACTPemphigus foliaceus is a superficial blistering disorder characterized by erosions and scaling in a seborrheic distribution. The condition typically occurs in healthy individuals but issues arise from delayed diagnosis. Many cases remain undiagnosed or misdiagnosed due to the lack of awareness of the condition. With use of common diagnostic tools, pemphigus foliaceus can be easily identified and monitored. Histological analysis exhibits "chicken wire" patterning along keratinocytes in the upper epidermis, whereas immunofluorescence study displays subcorn...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Mishma Farsi Cassandra M Johnson Kelly Segars Jonathan Rhim Source Type: research

Diagnostic utility of gingival biopsy for pemphigus vulgaris and mucosa membrane pemphigoid: A 10-year cohort study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - March 13, 2024 Category: Dermatology Authors: Junjiang Liu, Can Hu, Jing He, Jingtian Mu, Shimeng Wang, Qi Han, Jia Li, Mei Lin, Qinghong Gao, Fanglong Wu, Hongmei Zhou Source Type: research

Rituximab ‐induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review
Key Clinical MessageRituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab-related cutaneous complications will help them in detection and management.AbstractRituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface. Although it is used as promising treatment for pemphigus, nowadays it is also a new therapy for other autoimmune diseases including systemic...
Source: Clinical Case Reports - March 9, 2024 Category: General Medicine Authors: Leila Ghadirzade Arani, Shima Moslemi Haghighi, Soheila Nasiri, Sahar Dadkhahfar Tags: CASE REPORT Source Type: research

The Need of Differential Diagnosis Between Vulvar Lichen Sclerosus and Autoimmune Dermatoses in Adolescent Girls
AbstractIntroductionVulvar lichen sclerosus (VLS) is a chronic inflammatory condition affecting the anogenital region, which can manifest in prepubertal or adolescent patients. The prevailing theories point to autoimmune and genetic factors. The primary symptoms of VLS typically include vulvar itching, discomfort, dysuria, and constipation. Physical examination often reveals a characteristic figure 8 pattern, involving the labia minora, clitoral hood, and perianal region. However, these symptoms and the age of onset are nonspecific and require differentiation from autoimmune dermatoses such as bullous diseases, pemphigus...
Source: Dermatology and Therapy - March 7, 2024 Category: Dermatology Source Type: research

Pemphigus Vulgaris Successfully Treated With Bromocriptine
We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV.  J Drugs Dermatol. 2024;23(3):     doi:10.36849/JDD.7720e.PMID:38443120 | DOI:10.36849/jdd.7220 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Natalya Lyadova Narmin S Ghalichi Source Type: research

Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus
CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99    doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research